1)Boden WE, et al:Optimal medical therapy with or without PCI for stable coronary disease. N Engl J Med 356:1503-1516, 2007 PMID 17387127
2)Shaw L J, et al:Optimal medical therapy with or without percutaneous coronary intervention to reduce ischemic burden;Results from the Clinical Outcomes Utilizing Revascularization and Aggressive Drug Evaluation(COURAGE)trial nuclear substudy. Circulation 117:1283-1291, 2008 PMID 18268144
3)Hachamovitch R, et al:Comparison of the short-term survival venefit associated with revascularization compared with medical therapy in patients with no prior coronary artery disease undergoing stress myocardial perfusion single photon emission computed tomography. Circulation 107:2900-2906, 2003 PMID 12771008
4)Pijls NHJ, et al:Percutaneous coronary intervention of functionally nonsignificant stenosis. 5-year follow-up of the DEFER Study. J Am Coll Cardiol 49:2105-2111, 2007 PMID 17531660
5)Tonino PAL, et al:Fractional flow reserve versus angiography for guiding percutaneous coronary intervention. N Engl J Med 360:213-224, 2009 PMID 19144937
6)Bruyne BD, et al:Fractional flow reserve-guided PCI versus medical therapy in stable coronary disease. N Engl J Med 367:991-1001, 2012 PMID 22924638
7)Maron DJ, et al:Initial invasive or conservative strategy for stable coronary disease. N Engl J Med 382:1395-1407, 2020 PMID 32227755
8)Lopes RD, et al:Initial invasive versus conservative management of stable ischeic heart disease in patients with a history of heart failure or left ventricular dysfunction. Insights from the ISCHEMIA trial. Circulation 142:1725-1735, 2020 PMID 32862662
9)Chaitman BR, et al:Myocardial infarction in the ISCHEMIA trial;Impact of different definitions on incidence, prognosis, and treatment comparisons. Circulation 143:790-804, 2021 PMID 33267610
10)日本循環器学会,他:2022年JCSガイドライン フォーカスアップデート版 安定冠動脈疾患の診断と治療. https://www.j-circ.or.jp/cms/wp-content/uploads/2022/03/JCS2022_Nakano.pdf(2023年8月閲覧)